Eli Lilly and Company (LLY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $1.29T
Last updated: Nov 17, 2026 at 11:06 AM ET
Eli Lilly and Company (LLY) P/E Ratio & Valuation History
Eli Lilly and Company (LLY) trades at 44.9x trailing earnings and 14.8x sales. Its P/E of 44.9x is below its 5-year median of 46.0x. Its forward P/E is 29.0x. The median P/E across 9 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 54.8% higher over the next year. Its free cash flow yield is 1.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 44.9x |
| Forward P/E | 29.0x |
| Price to sales | 14.8x |
| Price to book | 31.8x |
| EV/EBITDA | 35.8x |
| Price to FCF | 65.0x |
| EV/FCF | 67.3x |
| PEG | 1.3 |
| FCF yield | 1.5% |
Historical Medians
Against its 10-year medians, its P/E is 48.2% above 30.3x, its P/S is 78.3% above 8.3x and its P/B is 0.3% above 31.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 44.9x | 46.0x | 30.3x |
| P/S | 14.8x | 13.6x | 8.3x |
| P/B | 31.8x | 35.4x | 31.7x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 19.7x in 2017 to 92.2x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $1,074.68 | 44.4x | 14.8x | 36.4x |
| 2024 | $772.00 | 59.4x | 15.5x | 49.1x |
| 2023 | $582.92 | 92.2x | 15.4x | 48.9x |
| 2022 | $365.84 | 46.1x | 11.7x | 32.6x |
| 2021 | $276.22 | 33.8x | 9.0x | 29.3x |
| 2020 | $168.84 | 21.3x | 6.3x | 28.6x |
| 2019 | $131.43 | 21.8x | 5.5x | 48.3x |
| 2018 | $115.72 | 20.8x | 5.6x | 12.4x |
| 2017 | $84.46 | 19.7x | 4.5x | 7.7x |
| 2016 | $73.55 | 20.9x | 3.7x | 5.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LLY
What is LLY's forward P/E ratio?
Eli Lilly and Company has a forward P/E ratio of 29.0x.
Is LLY stock overvalued?
GNG's valuation label for LLY is Undervalued. Its P/E of 44.9x compares with a median of 19.9x across 9 similar companies.
What is LLY's price to sales ratio?
Eli Lilly and Company has a price to sales ratio of 14.8x.
What is Eli Lilly and Company's average P/E ratio over 5 years?
Eli Lilly and Company's median P/E over the last 5 years is 46.0x, from 60 month-end values through Oct 2026.
What is LLY's PEG ratio?
Eli Lilly and Company has a PEG ratio of 1.3.
LLY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts